Oncosyne presented new research at ESMO TAT 2026 showing how patient-derived tumoroid models can support predictive biomarker discovery and strengthen decision-making in early oncology drug development.
In the poster, Spatial pharmacoproteomics analysis of patient-derived tumoroids from colorectal cancer to identify predictive biomarkers, the team demonstrated how combining functional drug testing with high-content spatial analysis generates deeper insight into therapy response in clinically relevant tumor models.
Throughout the meeting, researchers and industry partners highlighted the growing need for more patient-relevant biology earlier in development workflows. Patient-derived tumoroid testing is emerging as an important approach to prioritize candidates and combinations, support biomarker strategies, and reduce uncertainty before clinical evaluation.
Oncosyne carried out this work in collaboration with Akershus University Hospital and the Institute for Molecular Medicine Finland as part of its broader effort to generate decision-relevant data from clinical-grade tumor models in colorectal cancer.
The discussions at ESMO TAT 2026 further confirmed the increasing role of functional patient-derived models in improving translation from preclinical research to clinical development. 🔬